Skip to main content

Advertisement

Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

Fig. 2

Anti-lymphoma activity of BET bromodomain inhibitors on the DHL/THL cells. a–c WT- MYC, SH, DH, and TH harboring DLBCL cell lines were treated with 3 pharmacological BET bromodomain inhibitors I-BET (a), JQ1 (b), and OTX (c) for 72 h and proliferation was assessed by H3-thymidine incorporation assay. Data represent mean ± SD from three independent experiments. p < 0.05 value was significant for both the concentrations in all the cell lines tested

Back to article page